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ABSTRACT Asthma is a chronic inflammatory airway disease. Increase in airway inflammation is
hypothesised to contribute to worsening of asthma symptoms and deterioration in lung function, resulting in
the use of reliever medication. Short-acting β2-agonists only treat the symptoms, whereas an anti-inflammatory
reliever is believed to treat both symptoms and the underlying inflammation, thereby arresting the progression
to an exacerbation. As-needed budesonide/formoterol as an anti-inflammatory reliever reduces the risk of severe
exacerbations. However, supporting mechanistic evidence has not yet been described, specifically the temporal
dynamics of parameters including airway inflammation, over time and during asthma worsening.
The STIFLE study aims to characterise daily variability in airway inflammation, symptoms, lung function
and reliever use in people with asthma. This phase IV, open-label, parallel-group, multicentre, exploratory
study will enrol 60–80 adult patients with asthma receiving low- or medium-dose inhaled corticosteroids/
long-acting β2-agonists (EudraCT identifier number 2018-003467-64). Participants will be randomised 1:1 to
either as-needed budesonide/formoterol dry-powder inhaler or salbutamol reliever for 24 weeks, in addition
to their maintenance therapy. Daily data will be captured for fractional exhaled nitric oxide, spirometry,
asthma symptoms and medication use using devices connected to a smartphone via the STIFLE application.
STIFLE will thereby enable not only characterisation of the variability of airway inflammation and clinical
outcomes in relation to asthma worsening, but also elucidate the effect of as-needed budesonide/formoterol
on airway inflammation against a background of daily maintenance therapy.
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Using novel, home-based tools to generate new insights into the link between inflammation and
asthma attacks, the STIFLE study aims to increase understanding of the mechanisms behind the
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Introduction and study rationale
Asthma is a chronic inflammatory disease of the airways [1]. The inflammation is variable in terms of
intensity and is heterogeneous, with well-characterised subtypes that have different responses to therapy
[1, 2]. In parallel, variability in lung function, asthma symptoms and reliever medication use are
commonly observed over days and weeks [3–5]. Often, these periods, beyond baseline day-to-day or
week-to-week variability, are interspersed with significant exacerbations of symptoms [6], necessitating
increased reliever use and, potentially, the use of oral corticosteroids [7].
Treatment with inhaled corticosteroids (ICS) is the cornerstone of asthma management [7] and treatment
strategies targeted at inflammation (via maintenance of a normal airway eosinophil count) have been
shown to reduce the risk of severe exacerbations compared with strategies based on assessment of
symptoms, lung function and use of rescue treatment [8]. However, many patients, regardless of the
underlying disease severity, are not adherent with such treatment and rely on short-acting β2-agonists
(SABAs) for rapid relief of asthma symptoms [9]. Such over-reliance on SABAs is a concern since their
excessive use may worsen asthma control and increase the risk of fatal or near-fatal asthma [10, 11]. A
SABA does not address the underlying inflammation and increases the risk of exacerbations [12]. In
addition, even in patients whose disease is apparently controlled and who are adherent to maintenance
medication, exacerbations may still occur [9]. This suggests that, in such a variable condition, patients’
requirement for anti-inflammatory therapy varies and, in turn, represents an argument in favour of
providing increased doses of ICS when symptoms worsen. To this end, a combination of budesonide/
formoterol (ICS/fast-onset but long-acting β2-agonist (LABA)) as maintenance and reliever therapy has
been studied in several randomised controlled trials in patients with moderate-to-severe asthma [5, 13–16].
Results from these trials have demonstrated that as-needed use of budesonide/formoterol as an
anti-inflammatory reliever in addition to daily maintenance therapy is highly effective in reducing the risk
of severe exacerbations, with up to a 47% reduction versus comparator regimens that utilise a SABA as a
reliever [5, 13, 16]. In addition, as-needed budesonide/formoterol has been evaluated as a treatment option
for patients with mild asthma, as assessed in the SYGMA (Symbicort Given as Needed in Mild Asthma)
programme [17, 18], the PRACTICAL (Personalised Asthma Combination Therapy: with Inhaled
Corticosteroid and Fast Onset Long-Acting Beta Agonist) study [19] and the Novel START (Novel
Symbicort Turbuhaler Asthma Reliever Therapy) study [20]. In the latter study, the risk of severe
exacerbations was lower in the as-needed budesonide/formoterol group compared with as-needed SABA, a
finding that was paralleled by a reduction in exhaled nitric oxide fraction (FENO), consistent with an effect
of as-needed budesonide/formoterol on airway inflammation [20].
Hypothesis of the STIFLE study: use of anti-inflammatory reliever therapy in the
“window of opportunity”
The benefits of anti-inflammatory reliever therapy in reducing the risk of exacerbations are hypothesised
to be due to additional anti-inflammatory ICS therapy received at pivotal times [21], specifically during
the “window of opportunity” when inflammation-driven symptoms start to worsen (figure 1 and
supplementary video) [22, 23]. This is based on the work of TATTERSFIELD et al. [23], who evaluated all
severe exacerbations that occurred in the FACET (Formoterol and Corticosteroids Establishing Therapy)
study. Exacerbations were characterised by a gradual fall in peak expiratory flow (PEF) over 5–7 days,
followed by a more rapid fall over 2–3 days prior to an exacerbation. Furthermore, the change in PEF
occurred in parallel with an increase in symptoms and the use of SABA reliever, suggesting that a 2–3-day
window of opportunity exists when patients experience deteriorating symptoms and lung function but
have not yet deteriorated to the stage of requiring oral corticosteroids. Indeed, a post hoc analysis of FENO
data from the CHARISM (Childhood Asthma Respiratory Inflammatory Status Monitoring) study showed
an increase in FENO ∼10 days before a moderate exacerbation, with a significant increase 3 days
beforehand [24]. Together, these findings highlight an early opportunity to adjust treatment with an
increase in ICS to target the underlying flare-up of airway inflammation, thereby arresting progression to
exacerbation. In addition, against a background of budesonide/formoterol maintenance therapy, as-needed
formoterol demonstrated better exacerbation control than a SABA [14], likely due to a stabilising effect on
airway smooth muscle. Furthermore, LABAs may be particularly active against noneosinophilic
exacerbations [25].
However, supporting mechanistic evidence has not yet been described for as-needed budesonide/
formoterol, specifically the nature of the variations and temporal dynamics (patterns or trends with
respect to time) of airway inflammation, symptoms, lung function and reliever use, both over time and
during periods of symptom worsening. Consequently, the STIFLE study (EudraCT identifier number
2018-003467-64) has been designed to characterise the day-to-day relationship between such parameters,
and specifically in relation to worsening of symptoms in patients with asthma receiving as-needed
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budesonide/formoterol anti-inflammatory reliever or a SABA, against a background of budesonide/
formoterol maintenance therapy.
Design of the STIFLE study
STIFLE is a phase IV, randomised, active-comparator, open-label, parallel-group, multicentre, exploratory,
24-week study in adult asthma patients (⩾18 years of age) receiving Global Initiative for Asthma 2018 [26]
step 3 or step 4 treatment (low- or medium-dose ICS/LABA only). The study aims to characterise
variability in inflammation (FENO), symptoms, lung function and reliever use, on a daily basis, over time
(primary objective) and in the period surrounding an event (secondary objective). Events include severe
exacerbation, Composite Endpoint for Exacerbations (CompEx) [27], a single day with six or more
occasions of reliever medication use and FENO >50 ppb (table 1). Key inclusion and exclusion criteria are
shown in table 2. This study will consist of a screening visit (visit 1), a 2-week run-in period, a baseline
visit (visit 2) and a 24-week treatment period (visits 3 and 4) (figure 2). During the run-in period, patients
will receive maintenance budesonide/formoterol 100/6 µg or 200/6 µg dry-powder inhaler, two inhalations
twice daily (based on ongoing low- or medium-dose ICS/LABA, respectively, at study entry) and SABA
reliever (salbutamol 100 µg) as needed. At visit 2 (baseline visit, week 1), eligible patients will be
randomised 1:1 (stratified by ongoing low- or medium-dose of ICS/LABA at study entry) to receive
maintenance budesonide/formoterol (100/6 µg or 200/6 µg, two inhalations twice daily) with either
as-needed budesonide/formoterol (same dose as maintenance) or salbutamol (100 µg) as reliever for
24 weeks. Additional visits will be scheduled if a patient meets any of the criteria for an event during the
treatment period, including the first occurrence of a severe exacerbation, symptom worsening (decrease in
PEF, increase in reliever use or asthma symptoms) or a single day with six or more occasions of reliever
medication use. Informed consent will be obtained from all patients prior to initiation of study-related
procedures, sampling and analysis.
All patients will be provided with a kit containing a smartphone and four devices (a FENO monitoring device
(Vivatmo Me; Bosch, Waiblingen, Germany), a spirometer (Spirobank Smart; MIR, Rome, Italy) and two

























































































FIGURE 1 Proposed hypothesis of the mechanism of a) short-acting β2-agonist (SABA) reliever and
b) as-needed budesonide (BUD)/formoterol (FORM) as anti-inflammatory reliever therapy during worsening of
asthma symptoms that precedes an exacerbation. The effects of FORM are likely to be more complex and are
not presented in the graphs. SABA treats only symptoms and not the underlying inflammation.
Anti-inflammatory reliever therapy treats both symptoms and the underlying inflammation. Dashed lines
indicate asthma worsening in patients with SABA reliever use.
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TABLE 1 STIFLE study objectives and endpoints
Objectives Endpoints
Primary
To characterise descriptively# the relationship between airway
inflammation, asthma symptoms, lung function and reliever use,
in the two treatment arms measured daily over 24 weeks of
treatment
Individual patient profiles of daily variations over time in FENO
(morning), asthma symptom scores (morning and evening), PEF and
FEV1 (morning and evening), and reliever use
Secondary
To characterise descriptively# airway inflammation, asthma
symptoms, lung function and reliever use profiles surrounding
an event in the two treatment arms
Individual patient profiles of daily variations over time in FENO
(morning), asthma symptom scores (morning and evening), PEF and
FEV1 (morning and evening), and reliever use between 14 days prior
and 28 days after an event. Events include severe exacerbation¶,
CompEx (full criteria) [26], single day (in 24 h) with six or more
occasions of reliever medication use and FENO >50 ppb
Exploratory
To describe patterns of inflammatory biomarkers in the two
treatment arms at the start of an event+ (and every 4 days up to
12 days)
Individual patient profiles of inflammation biomarkers (blood
biomarkers including eosinophils, EDN and CRP; sputum and nasal
biomarkers) at the start of an event (and every 4 days up to 12 days)
To characterise descriptively the daily variations in nasal
biomarker measures during the first 30 days of treatment in the
two treatment arms
Individual patient profiles of daily variations over time in nasal
biomarkers during the first 30 days of treatment (subset of 30
patients)
Severe exacerbation events will be recorded, as they occur, on a case report form. Other events will be retrospectively defined and analysed
based on the data collected during the study. FENO: exhaled nitric oxide fraction; PEF: peak expiratory flow; FEV1: forced expiratory volume in 1 s;
CompEx: Composite Endpoint for Exacerbations; EDN: eosinophil-derived neurotoxin; CRP: C-reactive protein. #: this study has not been designed
or powered to test any statistical hypothesis relating to a difference between the treatment arms; instead, airway inflammation, symptoms, lung
function and reliever use profiles will be assessed descriptively and visually and will be modelled for each patient individually and by treatment,
both over the 24-week period and during the time surrounding the various events. ¶: use of systemic corticosteroids for ⩾3 days, an emergency
department visit due to asthma that requires systemic corticosteroids or inpatient hospitalisation due to asthma. +: events of interest include the
first occurrence of either a severe exacerbation, symptom worsening (deterioration in two or more variables for two or more consecutive days:
⩾15% decrease in PEF, ⩾1.5 times increase in inhalations of reliever medication or ⩾1 increase in asthma symptom score (or the absolute
maximum score of 3), in the morning or evening, as compared with baseline), or a single day (in 24 h) with six or more occasions of reliever use.
TABLE 2 Key inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Male and/or female patients aged ⩾18 years
Physician-diagnosed asthma for ⩾6 months
prior to visit 1
Use of low- or medium-dose ICS/LABA# for
⩾3 months prior to visit 1
Worsening of asthma symptoms requiring
overuse¶ of reliever medication at least once
within 30 days prior to visit 1
Patient-reported history of one or more severe
asthma exacerbations requiring treatment
with systemic corticosteroids during the
12 months prior to visit 1, except in the
previous 30 days
Ability to perform FENO and spirometry
assessments at home and complete an
asthma symptom diary on a regular basis
Patients with any significant disease or disorder or evidence of drug/substance abuse that
would pose a risk to patient safety, interfere with study conduct or impact study results
Any asthma worsening requiring a change in treatment other than the prescribed reliever
medication within 30 days prior to visit 1
Medical history of life-threatening asthma, including intubation and admission to an
intensive care unit
Medical conditions (except allergic rhinitis) or medications (except ICS) that may influence
FENO
Concurrent respiratory disease (e.g. cystic fibrosis, idiopathic pulmonary fibrosis or
pulmonary arterial hypertension)
Acute upper or lower respiratory infections requiring antibiotics or antiviral medication
within 30 days prior to visit 1 or during screening/run-in period
A severe exacerbation (resulting in ⩾3 days of oral corticosteroids (or one depot
intramuscular injection of glucocorticosteroid), an urgent care or emergency room visit
resulting in treatment with systemic corticosteroids or an inpatient hospitalisation due to
asthma) within 30 days prior to screening
Any disease, other than asthma, or procedure that may necessitate the use of oral/systemic
corticosteroids during the treatment period
Current tobacco smoking or a history of smoking for ⩾10 pack-years
ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; FENO: exhaled nitric oxide fraction.
#: low ICS doses (daily): beclometasone
dipropionate hydrofluoroalkane (HFA) (100–200 µg), budesonide dry-powder inhaler (DPI) (200–400 µg), ciclesonide HFA (80–160 µg),
fluticasone furoate DPI (100 µg), fluticasone propionate DPI or HFA (100–250 µg), mometasone furoate (110–220 µg) and triamcinolone
acetonide (400–1000 µg); medium ICS doses (daily): beclometasone dipropionate HFA (>200–400 µg), budesonide DPI (>400–800 µg),
ciclesonide HFA (>160–320 µg), fluticasone propionate DPI or HFA (>250–500 µg), mometasone furoate (>220–440 µg) and triamcinolone
acetonide (>1000–2000 µg). ¶: overuse was defined as more than the standard use of reliever for individual patients.
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smartphone via the STIFLE application (AstraZeneca, Cambridge, UK) and will receive training on its use.
Daily, at home, patients will perform FENO measurements (morning) and spirometry assessments (PEF and
forced expiratory volume in 1 s (FEV1), morning and evening) and complete an asthma symptom diary that
includes reliever medication use (morning and evening). Data from these four devices and an embedded
asthma symptom diary will be recorded in the STIFLE application through an integrated approach (figure 3).
∼30 patients who agree to participate in a nasal biomarker substudy of STIFLE will be shown how to collect a
nasal absorption sample (synthetic absorptive matrix (SAM) [28]), and will be provided with a kit and
instructions for collecting the samples at home. These patients will collect daily morning nasal samples for the
first 30 days of randomised treatment for the evaluation of inflammatory biomarkers.
At all clinic visits, FEV1 will be assessed (by clinic spirometry equipment), safety (adverse events) will be
evaluated, and blood samples will be collected for haematology (including eosinophils), clinical chemistry
and C-reactive protein analyses. 60–80 patients will be randomised from three sites in the UK to achieve
⩾50 patients who will complete the 24-week study. It is anticipated that half of these patients will meet the
criteria for an event.
A short review: FENO
Daily measurement of FENO is an important methodological component of the STIFLE study. FENO is a
simple, noninvasive, quantitative, highly sensitive and safe measure of airway inflammation [29]. FENO is a
surrogate marker for eosinophilic airway inflammation and is used to determine the potential need for and
likelihood of response to ICS, to optimise the doses of anti-inflammatory medications, and to unmask
poor adherence to ICS [29]. A strength of the STIFLE study is that we will measure FENO concentrations
daily, against a background of maintenance ICS therapy, to determine if variability in FENO around the
time of an exacerbation can be detected and, therefore, whether it is a useful biomarker of type 2
inflammation in a cohort of treated patients with moderate asthma.
Eligibility criteria
FEV1, prior and concomitant medication,
serious AEs and AEs leading to treatment
discontinuation, pregnancy test, clinical
chemistry/urinalysis assessments, haematology
assessments (including eosinophils), blood
sample for C-reactive protein, plasma and 
serum samples for exploratory biomarkers
Nasal absorption samples for inflammation
biomarkers
Blood sample for eosinophil-derived neurotoxin
Vital signs, physical examination
Demographics, medical history and comorbid
conditions, BMI
Visit 1 (week –2)
BUD/FORM 100/6 µg# × 2 
twice daily + salbutamol 
100 µg as needed or
BUD/FORM 200/6 µg# × 2 
twice daily + salbutamol 
100 µg as needed
Visit 2 (week 1) Visit 3 (week 12)
Event visit+: days 1, 4, 8 and 12 after event onset




































BUD/FORM 100/6 µg# × 2 twice daily + salbutamol 100 µg as needed or
BUD/FORM 200/6 µg# × 2 twice daily + salbutamol 100 µg as needed
BUD/FORM 100/6 µg# × 2 twice daily + BUD/FORM 100/6 µg# as needed or
BUD/FORM 200/6 µg# × 2 twice daily + BUD/FORM 200/6 µg# as needed
FIGURE 2 Study design. BMI: body mass index. #: patients on low-dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) at study entry
will receive budesonide (BUD)/formoterol (FORM) 100/6 µg and those on medium-dose ICS/LABA at study entry will receive BUD/FORM 200/6 µg.
¶: randomisation criteria are adherence (completed ⩾80% of asthma assessments (exhaled nitric oxide fraction (FENO) and spirometry
measurements, and completing the asthma symptom diary) at home during the run-in period) and reliever medication use (used reliever
medication for 2–8 days out of the last 10 days of the run-in period). +: event visit assessments are prior and concomitant medication (days 1 and
12), serious adverse events (AEs) and AEs leading to treatment discontinuation, clinical chemistry, urinalysis, haematology (including eosinophils),
spontaneous sputum for inflammatory biomarkers, nasal absorption samples for inflammatory biomarkers, blood sample (eosinophil-derived
neurotoxin and C-reactive protein), plasma and serum samples for exploratory biomarkers. §: daily assessments at home are FENO, peak
expiratory flow (PEF) and forced expiratory volume in 1 s (FEV1), and completing the asthma symptom diary before taking the study medication in
the morning; and PEF and FEV1, and completing the asthma symptom diary before taking the study medication in the evening.
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How will the STIFLE study help understand the day-to-day relationship between
airway inflammation, symptoms and lung function in patients with asthma?
To our knowledge, STIFLE will be the first study specifically designed to investigate daily airway
inflammatory patterns and associated variability in symptoms, lung function and reliever medication use
in patients with asthma. An increase in airway inflammation is thought to contribute to worsening of
asthma symptoms and deterioration in lung function, requiring the use of reliever medication. However,
the time perspective of various parameters before and after asthma worsening is largely unknown,
including the order of appearance, magnitude and timeframe in relation to worsening. Therefore, the
STIFLE study will help clarify these differences and provide an understanding of the temporal dynamics of
these parameters, and specifically in relation to asthma worsening.
High “as-needed” reliever use is a robust measure of asthma instability [22]. Results from an exploratory
analysis of two randomised controlled trials reported that budesonide/formoterol maintenance and
anti-inflammatory reliever therapy reduced the incidence of high reliever use episodes (more than six
inhalations a day) and exacerbation burden immediately following these high-use episodes compared with
ICS/LABA maintenance plus SABA reliever therapy [22]. Consequently, STIFLE will also help establish
whether the hypothesised mechanistic benefit of as-needed budesonide/formoterol as anti-inflammatory
reliever relates to the timely and rapid suppression of airway inflammation (and related symptoms) by ICS
during the window of opportunity [21, 22], as compared with only symptom relief provided by a SABA
(figure 1). The concentration of ICS in lung tissue has been shown to decline over time (between
maintenance doses) [30], with concentrations being ∼10% of peak values within 6 h of inhalation; thus,
as-needed ICS may help restore concentrations when the levels of ICS are suboptimal between scheduled
maintenance doses [14]. The importance of increasing ICS dosing frequency is supported by the results of











PEF and FEV1 (morning and evening)
Asthma symptoms (morning and evening)
Reliever use (morning and evening)
Alerts#
FIGURE 3 Integrated approach to data collection. PEF: peak expiratory flow; FEV1: forced expiratory volume in 1s; FENO: exhaled nitric oxide
fraction. #: the patient and the investigator will receive alerts from the STIFLE system regarding event visits (in relation to the exploratory
objective event) due to symptom worsening (based on peak expiratory flow (PEF), reliever use and symptom score criteria) or due to a single day
with six or more occasions of reliever medication use. Patients will also be instructed to contact the study site to arrange an event visit if they
experience a severe exacerbation. Patients and investigators will be blinded to all data collected from these devices. Asthma symptoms during the
night and day will be recorded by the patient twice daily in the asthma symptom diary, according to the following scoring system: 0, no asthma
symptoms; 1, “you are aware of your asthma symptoms, but you can easily tolerate the symptoms”; 2, “your asthma is causing you enough
discomfort to cause problems with normal activities (or with sleep)”; 3, “you are unable to do your normal activities (or to sleep) because of your
asthma”.
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budesonide four times daily dosing compared with two times daily dosing, while providing the same total
daily dose [31]. In addition to the timely increase in ICS dose, the rapid onset of action of ICS is of
particular importance, with a wealth of evidence supporting the rapid anti-inflammatory effect of inhaled
budesonide (with or without formoterol) [32–35]. Indeed, results from a randomised controlled trial in 41
patients with stable asthma reported a significant reduction in sputum eosinophils and an improvement in
airway responsiveness within 6 h of budesonide inhalation [32]. Furthermore, a systemic
anti-inflammatory effect on circulating lymphocytes within 30 min of inhalation with budesonide/
formoterol has been demonstrated [34]. Additionally, budesonide/formoterol has been reported to prevent
asthma deterioration and significantly improve baseline FEV1 at 30 min following a low-dose allergen
exposure in patients with intermittent allergic asthma [35].
Notably, the STIFLE study will incorporate several important methodological components. The main
outcomes will be based on daily measurements, including local airway inflammation as measured by FENO
concentrations taken at home. To date, very few studies have evaluated FENO in the setting of acute
exacerbations and those that have report varying results [36–38]. Results from a cross-sectional study in a
paediatric emergency department reported that FENO concentrations during an exacerbation did not
correlate with asthma severity and had limited utility in the management of acute asthma [36]. In contrast,
in adult patients with moderate-to-severe asthma, a significant increase in FENO concentrations during
exacerbations compared with baseline in certain patients was reported [37]. In a sample of emergency
department patients with acute exacerbations of asthma, FENO measurements were poorly reproducible
and did not correlate with asthma severity [38]. However, a significant increase in FENO was reported
during 3 days before until 4 days after moderate exacerbations in children with asthma [24]. The results
from STIFLE are therefore expected to contribute to this knowledge base. Although FENO measurements
have been implemented in many asthma trials, including studies utilising daily, domiciliary methods for
capturing FENO [39, 40], a novel aspect of this study is that daily home assessments of FENO will be used
to determine variability and to compare with other parameters (lung function, reliever use and symptoms)
in a real-time environment to assess maintenance plus SABA versus maintenance plus anti-inflammatory
reliever therapy over 6 months.
A potential limitation of using FENO measurements is that rhinitis and allergic comorbidities in patients
with asthma may also lead to changes in FENO levels [41]. However, in addition to FENO, other biomarkers


























FIGURE 4 Examination of endpoints over 24 weeks and specifically in relation to an event. The graphs are for
representation only. The variables may or may not show parallel changes at a specific time point. Results
from the STIFLE study would potentially provide an understanding of the temporal dynamics of these
parameters.
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absorption biomarkers, will also be measured to explore patterns of inflammation. As patients will be
performing FENO and spirometry assessments at home, it is necessary that they use these devices correctly.
Spirometers can be difficult to use in the community and challenging to interpret. However, all patients
are trained on device use. Moreover, there is a precedence for the use of the spirometer in the home
environment [42, 43].
Another important feature of the study design of STIFLE is the examination of the temporal dynamics of
clinical parameters and local inflammation in relation to an event (figure 4), which may provide insights
into the inflammatory mechanism of worsening symptoms and lung function and highlight the benefits of
an anti-inflammatory reliever compared with a SABA reliever. Notably, STIFLE will include patients on a
background of ICS/LABA maintenance since variability in lung function, asthma symptoms and reliever
medication use are also observed in patients receiving such therapy [5, 9], many of whom continue to be
at risk of exacerbations even when adherent to therapy [44].
STIFLE will also be among one of the first prospective studies to use CompEx, an extended definition of
asthma exacerbations that combines diary-based events (clinically relevant asthma deteriorations) with the
traditional definition of severe exacerbations [27]. Since severe exacerbations are rare events, clinical trials
using such events as the primary outcome measure require large sample sizes and a long study duration to
evaluate treatment effects. Thus, CompEx, which mirrors results observed with the severe
exacerbation-validated outcome [27], was incorporated into the STIFLE study because it allows for the
evaluation of clinically relevant worsening in this clinical trial of short duration and with relatively few
patients.
Conclusion
In summary, the temporal dynamics of clinical parameters and airway inflammation are largely unknown
in patients with asthma, and the mechanistic evidence for the anti-inflammatory effect of as-needed
budesonide/formoterol has not been described. STIFLE is expected to provide insights into the real-time
day-to-day relationship between airway inflammation, lung function, asthma symptoms and reliever use in
such patients, including the temporal dynamics of various parameters surrounding events. Results will
further elucidate the anti-inflammatory effect of budesonide/formoterol as an anti-inflammatory reliever
against a background of regular maintenance therapy.
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